Prostaglandin F2alpha anticorps (FITC)

N° du produit ABIN2178429

Cet anticorps anti-Prostaglandin F2alpha est un anticorps Lapin Polyclonal détectant Prostaglandin F2alpha dans IF (p). Adapté pour Others.

Aperçu rapide pour Prostaglandin F2alpha anticorps (FITC) (ABIN2178429)

Antigène: Prostaglandin F2alpha

Reactivité: Others

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Prostaglandin F2alpha est conjugé à/à la FITC

Application: Immunofluorescence (Paraffin-embedded Sections) (IF (p))

Détail du produit anti-Prostaglandin F2alpha anticorps (FITC)

Réactivité croisée: Rat

Réactivité croisée (Details): PGF2 Alpha

Purification: Purified by Protein A.

Immunogène: KLH conjugated to PGF2 Alpha

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur Prostaglandin F2alpha

Antigène: Prostaglandin F2alpha

Autre désignation: Pgf2 alpha

Sujet:

Synonyms: Prostaglandin F2 Alpha, PGF2 Alpha, 5Z,9,11,13E,15S-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt, PGF2−,Tris.

Background: Luteolytic prostaglandin that induces parturition. Potent vasoconstrictor of pulmonary, coronary, and cerebral arteriole beds. A positive feedback loop between endometrial PG F2 and luteal oxytocin is responsible for completion of luteolysis.Luteolytic prostaglandin that induces parturition. Potent vasoconstrictor of pulmonary, coronary, and cerebral arteriole beds. Also stimulates contraction of smooth muscle, such as in bronchi, with possible involvement in asthma. This effect is at least partially mediated through tachykinin release.